The Quantellect read.As of Nov 19, 2026, 22 active firms cover Biomarin Pharmaceutical Inc: 18 rate it Buy or better, 4 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets range widely, $60.00 to $122.00 (about 2.0x), a sign of real disagreement on valuation. The average target of $89.10 sits 45% above the current $61.38. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 16 to 18 over recent months. On the fundamentals, the Street sees revenue growth near 20% this year and 14% next, consensus EPS building from about $1.47 next quarter toward $6.32 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS22 active firms
Buy
Strong Buy00%
Buy1882%
Neutral418%
Sell00%
Strong Sell00%
Based on 22 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$89.10
+45.2% upside
Average target across 21 active firms as of Nov 19, 2026 vs $61.38 current
Highest Target$122.00
Average Target$89.10
Lowest Target$60.00
Detailed analyst forecasts for BMRN
Showing 1–21 of 21 named analysts shown · 22 active firms in the rating projection
As of Nov 19, 2026, 18 of 22 active firms rate BMRN a Buy (4 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
BMRN EPS & revenue forecast
EPS · NEXT QUARTER
$1.47
Range $1.33 – $1.63 · 8 analysts · +93% YoY
Next period, 8 analysts expect Biomarin Pharmaceutical Inc to earn $1.47 a share (range $1.33 – $1.63), versus $0.76 a year earlier. Full-year consensus is $3.03, growing to $6.32 the year after.
REVENUE · NEXT QUARTER
$1.1B
Range $997.0M – $1.1B · 8 analysts · +35% YoY
Revenue is expected to reach $1.1B (range $997.0M – $1.1B), +35.0% year-over-year. Full-year consensus is $3.9B, rising to $4.4B next year.
Top analysts covering Biomarin Pharmaceutical Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on BMRN.
#1
Luca Issi
RBC Capital · Rank #76
Neutral
$60.00-2.2% to target
Overall win rate
49%
+ Follow
#2
Jessica Fye
JP Morgan · Rank #100
Buy
$87.00+41.7% to target
Overall win rate
54%
+ Follow
#3
Jason Gerberry
B of A Securities · Rank #160
Buy
$83.00+35.2% to target
Overall win rate
47%
+ Follow
#4
Joseph Schwartz
Leerink Partners · Rank #242
Neutral
$62.00+1.0% to target
Overall win rate
36%
+ Follow
#5
Debjit Chattopadhyay
Guggenheim · Rank #248
Buy
$86.00+40.1% to target
Overall win rate
39%
+ Follow
BMRN stock forecast FAQ
What is BMRN's average 12-month price target?+
The 21 active firms with a live target average $89.10 for Biomarin Pharmaceutical Inc over the next 12 months, ranging from a $122.00 high to a $60.00 low, as of Nov 19, 2026.
Is BMRN stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 22 active firms as of Nov 19, 2026, 18 rate it Buy or Strong Buy, 4 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for BMRN?+
The Street-high target is $122.00 (Morgan Stanley), and the Street-low is $60.00 (HC Wainwright & Co.). The average of all 21 active-firm targets is $89.10.
How many active Wall Street firms cover BMRN?+
22 active firms have a recognized rating on Biomarin Pharmaceutical Inc as of Nov 19, 2026, and 21 active firms carry a live 12-month price target.
Who is the most accurate analyst covering BMRN?+
Among analysts who currently cover BMRN, Luca Issi of RBC Capital has the strongest overall Quantellect track record (Rank #76). Their current call is Neutral with a $60.00 target.
What is Biomarin Pharmaceutical Inc's projected EPS for next quarter?+
The consensus estimate is $1.47 per share (range $1.33 – $1.63) across 8 analysts. Full-year EPS is projected at $3.03, rising to $6.32 the following year.
How much revenue is Biomarin Pharmaceutical Inc expected to report next quarter?+
Consensus revenue is $1.1B (range $997.0M – $1.1B). Full-year revenue is projected at $3.9B, growing to $4.4B next year.
Have analysts been upgrading or downgrading BMRN lately?+
As of Nov 19, 2026, 18 of 22 active firms rate BMRN a Buy (4 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their BMRN calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.